Novel pharmacological agents in clinical development for solid tumours

G. K. Dy, P. Haluska, Alex Adjei

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

For decades, cancer therapy has focused on DNA-directed mechanisms of cytotoxicity, utilising agents with limited efficacy and significant toxicity. Recent advances in tumour biology have elucidated the molecular pathways implicated in the pathogenesis and progression of cancers and have resulted in the discovery of a variety of novel molecular targets for therapeutic intervention. Promising novel agents targeting signal transduction pathways, cell cycle regulation, angiogenesis and apoptosis are in clinical testing and are discussed in this review.

Original languageEnglish (US)
Pages (from-to)2059-2077
Number of pages19
JournalExpert Opinion on Investigational Drugs
Volume10
Issue number12
DOIs
StatePublished - 2001

Fingerprint

Pharmacology
Neoplasms
Signal Transduction
Cell Cycle
Apoptosis
DNA
Therapeutics

Keywords

  • Angiogenesis
  • Antisense oligonucleotide
  • Cyclin-dependent kinase
  • Extracellular matrix
  • Farnesyltransferase inhibitors
  • Heat shock protein
  • Monoclonal antibodies
  • Proteasome
  • Protein kinase C inhibitors
  • Ras
  • Receptor tyrosine kinase inhibitors
  • Signal transduction
  • Ubiquitin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Novel pharmacological agents in clinical development for solid tumours. / Dy, G. K.; Haluska, P.; Adjei, Alex.

In: Expert Opinion on Investigational Drugs, Vol. 10, No. 12, 2001, p. 2059-2077.

Research output: Contribution to journalArticle

@article{07e5e19153b74e009eb7eb2703ce7104,
title = "Novel pharmacological agents in clinical development for solid tumours",
abstract = "For decades, cancer therapy has focused on DNA-directed mechanisms of cytotoxicity, utilising agents with limited efficacy and significant toxicity. Recent advances in tumour biology have elucidated the molecular pathways implicated in the pathogenesis and progression of cancers and have resulted in the discovery of a variety of novel molecular targets for therapeutic intervention. Promising novel agents targeting signal transduction pathways, cell cycle regulation, angiogenesis and apoptosis are in clinical testing and are discussed in this review.",
keywords = "Angiogenesis, Antisense oligonucleotide, Cyclin-dependent kinase, Extracellular matrix, Farnesyltransferase inhibitors, Heat shock protein, Monoclonal antibodies, Proteasome, Protein kinase C inhibitors, Ras, Receptor tyrosine kinase inhibitors, Signal transduction, Ubiquitin",
author = "Dy, {G. K.} and P. Haluska and Alex Adjei",
year = "2001",
doi = "10.1517/13543784.10.12.2059",
language = "English (US)",
volume = "10",
pages = "2059--2077",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Novel pharmacological agents in clinical development for solid tumours

AU - Dy, G. K.

AU - Haluska, P.

AU - Adjei, Alex

PY - 2001

Y1 - 2001

N2 - For decades, cancer therapy has focused on DNA-directed mechanisms of cytotoxicity, utilising agents with limited efficacy and significant toxicity. Recent advances in tumour biology have elucidated the molecular pathways implicated in the pathogenesis and progression of cancers and have resulted in the discovery of a variety of novel molecular targets for therapeutic intervention. Promising novel agents targeting signal transduction pathways, cell cycle regulation, angiogenesis and apoptosis are in clinical testing and are discussed in this review.

AB - For decades, cancer therapy has focused on DNA-directed mechanisms of cytotoxicity, utilising agents with limited efficacy and significant toxicity. Recent advances in tumour biology have elucidated the molecular pathways implicated in the pathogenesis and progression of cancers and have resulted in the discovery of a variety of novel molecular targets for therapeutic intervention. Promising novel agents targeting signal transduction pathways, cell cycle regulation, angiogenesis and apoptosis are in clinical testing and are discussed in this review.

KW - Angiogenesis

KW - Antisense oligonucleotide

KW - Cyclin-dependent kinase

KW - Extracellular matrix

KW - Farnesyltransferase inhibitors

KW - Heat shock protein

KW - Monoclonal antibodies

KW - Proteasome

KW - Protein kinase C inhibitors

KW - Ras

KW - Receptor tyrosine kinase inhibitors

KW - Signal transduction

KW - Ubiquitin

UR - http://www.scopus.com/inward/record.url?scp=0035218360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035218360&partnerID=8YFLogxK

U2 - 10.1517/13543784.10.12.2059

DO - 10.1517/13543784.10.12.2059

M3 - Article

C2 - 11772306

AN - SCOPUS:0035218360

VL - 10

SP - 2059

EP - 2077

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 12

ER -